

The logo for amoéba features a stylized circular shape composed of two overlapping curved segments. The top segment is a vibrant blue, and the bottom segment is a bright green. The word "amoéba" is written in a clean, white, lowercase sans-serif font, centered horizontally and partially overlaid by the logo.

amoéba

ROADSHOW PRESENTATION

2022

DISCLAIMER

When receiving this presentation or participating in this meeting, you acknowledge having taken note of the following restrictions.


The present document and the information contained in the presentation are strictly confidential. **This document cannot be copied, reproduced, distributed, published or otherwise divulged, directly or indirectly, in whole or in part, to any other person (within or outside your company).** In particular, neither this document, nor any part or copy of it can be distributed, directly or indirectly in the United States, Canada, Australia or Japan. Non-compliance with these restrictions can lead to violation of legal restrictions in some countries.

This presentation is not, nor is it a part of, and should not be interpreted as, an offer of subscription to securities or a solicitation for subscription to securities in France, the United States or any other country. Securities can only be offered or sold in the United States after registration in line with the 1993 U.S. Securities Act, as modified, (hereafter, the “**Securities Act**”) or in the case of exemption from this obligation to register. This presentation is not a prospectus. No offer to the public of financial instruments will be made in France before delivery of approval by the Authority regulating financial markets of a prospectus (the “**Prospectus**”) in line with the dispositions set out in Directive 2003/71/CE. Any decision to acquire financial instruments must be made solely on the basis of the information contained in the Prospectus. No offer to the public of financial instruments will be made in any jurisdiction, except in France. In particular, no financial instrument will be registered in line with the Securities Act, or with any authority for any of the States or jurisdictions in the United States.

This presentation only contains summary information and it is in no case an exhaustive presentation. The information contained in this document, whether from internal or external sources, is presented solely on an indicative basis, and it has no contractual value. The information contained in this presentation is up to date on the day of the presentation. Some of the information contained in this presentation and other declarations or documents, published or to be published by Amoeba (the “**Company**”) are not factual elements but prospective statements. These statements are based on opinions, expectations and hypotheses, including statements relating to the Company’s current and future commercial strategy, or those relating to the distribution environment in which the Company functions, and harbour known and unknown risks, uncertainties or other factors. The Company’s results, performances or creations, the sector results or any other event could be significantly modified relative to the projections expressly or indirectly described in this presentation. The Company, Bryan, Garnier & Co and Portzamparc have not provided any declaration or explicit or implicit guarantee as to the accuracy, sincerity, exhaustivity or relevance of the information and opinions contained in the present document. The Company’s responsibility, and that of Bryan, Garnier & Co and Portzamparc cannot be engaged (in particular for reasons of negligence) for any prejudice resulting from any use of this presentation or its contents, or linked in any way to this presentation. This information can be subject at any time to modifications, including and not limited to, due to changes to the applicable regulations or market conditions. The Company, Bryan, Garnier & Co, or Portzamparc are not, and cannot be, under any obligation to update this information. In the hypothetical situation where an offer of financial instruments is made by the Company in the future, investors must found their decision to invest solely on the basis of (i) the Prospectus or any other similar document which must be prepared by the Company as part of the offer, and in particular the risk factors described therein, (ii) any notification published by the Company modifying the terms of the offer, and (iii) any examination of the Company considered necessary by a potential investor. You must not accord excessive significance to the information contained in this presentation in terms of its sincerity, exhaustivity, accuracy or relevance. It is the responsibility of each potential investor, if an offer of financial instruments is made in the future, to carefully examine the Prospectus and independently assess the risks and advantages of the offer.

Market data and some sector forecasts included in this presentation were obtained from internal surveys, estimations, reports and relevant studies, as well as from market studies, publications or publicly available information. The latter were not the subject of independent verification by the Company, Bryan, Garnier & Co or Portzamparc, or their respective subsidiaries, social agents, directors, advisers or employees. The Company, Bryan, Garnier & Co and Portzamparc do not declare or explicitly or implicitly guarantee the accuracy, sincerity, exhaustivity or relevance of the information contained in the present document.

AMOEBEA'S VALUATION



* Functional plant / investment

AMOEBAS POSITIONING



Vines

€ 800M
(powdery and mildew)



Strawberry

Vegetables

€ 600M



Potato

€ 250M



Rice

Env. € 1000 M



Banana

Env. € 500 M



In the testing process

Arboricultures and others

Env. € 100 M



Wheat

€ 2 400M



Soybeans

€ 2 100M

Global Market potential : € 7 750 Mds

BIOCIDE, A VALUABLE ASSET OF AMOEBA



The first biological biocide for industrial water treatment

- A **patented innovation** in a sector that has been stagnant for 50 years
- **Favorable pre-decision in the USA** for use in closed cooling systems (definitive at the end of 2022)

\$ 10 M

Of construction costs for the plant in the USA



High profitability on sales due to remarkable industrial efficiency

\$ 200 M

Per year of achievable market potential in the US

2024 FORECAST



To guarantee the emergence of a **future French world leader** in biocontrol



Contribute to the creation of a **biocontrol industrial network** in France

Thanks to our solid pillars



Scientific maturity

- 10 years of R&D
- 9 scientific publications



Regulatory maturity


- Europe: Recommendation for approval by Austria (April 2022)
- USA: Evaluation expected H2-2022

TOWARDS A NEW REQUEST TO THE MARKET

« Since the creation of Amoéba, our funding has allowed us to reach a *level of maturity on our 3 pillars*: scientific, industrial and regulatory. Our objectives have been reached, notably by the *completion of numerous field trials*, the *positive recommendation* of Austria for the approval of our biocontrol active substance and the *full early refund of our loan from the EIB*.

Amoeba can now consider a *new phase of its development and financing* with the *construction of a plant* dedicated to the biocontrol application in view of the commercialization of its product worldwide, while continuing our researches of new opportunities based on the use of the *Willaertia magna C2c Maky amoeba*. »

Fabrice Plasson, Chairman & CEO of Amoéba



1

AMOEBIA PRESENTATION




ABOUT AMOEBBA



Amoéba is a Lyon-based biotech company specialized in the treatment of microbiological risk for natural resources.

1 microorganism, 2 applications



Live amoeba
BIOCIDE

Dedicated to industrial water treatment



Lysate of amoeba
BIOCONTROL PRODUCT

Dedicated to crop protection

OUR VISION AND MISSION



Ensuring a **sustainable future** by offering biological alternatives that respect human health and the environment



Develop a **scientific and industrial** expertise to contribute to expand the offer of eco-friendly products



Demonstrate our **relevance and positive influence** in targeted sectors by 2024



Leading the way for other alternatives to chemical treatment of key resources

AMOEBA KEY FIGURES



25

Millions of euros invested in R&D since 2010



26

Employees in France



1

Industrial center dedicated to our production

BOARD OF DIRECTORS



Fabrice Plasson

CEO

*Expert in life science and
biotechnologies*



Valérie Filiatre

Administrator &

Chief Financial Officer

*Expert in business administration
and finance*



Bernard Ambolet

Administrator

*Expert in agriculture and
Biocontrol*



Pierre Morgon

Administrator

Expert in life and health sciences



Sylvie Guinard

Administrator

Expert in industrial processes



Philippe Dujardin

Administrator

Expert in finance and strategy

COMITE DE DIRECTION



Fabrice Plasson

CEO

*Expert in life science and
biotechnologies*



Valérie Filiatre

Administrator &

Chief Financial Officer

*Expert in business administration
and finance*



Jean-Luc Souche

Business Developer Biocontrol

Specialist in plant protection



Sandrine Troussieux

Scientific Director

*Dr. in Sciences, specialized in
environmental microbiology*



Jean-Baptiste Eberst

Regulatory affairs Director

Expert in regulatory affairs



Hervé Testeil

Industrial Director

*Industrial expert in pharmaceuticals,
medical devices and biotechnologies*



2

FINANCIAL INFORMATION

FINANCING AND SHAREHOLDING



€ 13.2 M

Raised during the IPO in July 2015

€ 14.7 M

Raised in 2016 by private placement

€ 5 M

Financing agreement with the European Investment Bank (EIB) in 2017

€ 15,8 M

OCAPI with Nice & Green between 2018 and 2021


€ 6 M

Other funds raised, subsidies, refundable advances and loans

€ 55 M

Invested in the Company since its creation

Distribution of shareholding



■ Individual shareholders

■ CEO and historical shareholders

FINANCIAL SITUATION



BURN RATE

2020

€ 410 K

2021

€ 370 K

EIB DEBT

Refunded in June 2022

2020

€ 7,9 M

2021

€ 6,1 M

EQUITY

2020

€ 2,0 M

2021

€ 0,2 M

CASHFLOW

2020

€ 5 M

2021

€ 7,3 M





3

BIOCONTROL

EUROPEAN OBJECTIVE

To find "green" alternative but equally effective solutions.

CURRENT ISSUES

- Pesticide resistance
- Demand for organic products from farmers and consumers
- Low efficiency of current biofungicides
- Very few biofungicides available on row crops (cereals, soybeans..)



High environmental impact

78% reduction of insects between 1989 and 2013



Regulatory pressure

Regulation 1107/2009, SUD directive, IPM, organic farming



Limited biocontrol solutions

Ancient pesticides increasingly banned (EU), including copper submitted for re-evaluation in 2026



Public health issues

46% of the foodstuffs analyzed by EFSA are contaminated by pesticide residues



A 100% natural biofungicide


50-80% Effectiveness in
fields

300 In-field trials by
Amoéba
since 2019

180 In-field trials by
partners
since 2019



Facilitating the transition from conventional to organic agriculture



Thanks to our solution :

- A **unique dual mode of action** (elicitor and fungicide)
- A **wide spectrum** of activity (vineyards, vegetables, potatoes, cereals...)
- A **good complementary with conventional** products

KEY FACTORS OF SUCCESS



An **innovative and unique product** from a class of microorganisms never used before in agriculture: **amoebas**



An active substance **recommended for approval** by the Rapporteur Member State (Austria)



A product with **no hazard class** and a **low risk profile**



A product with **no residue limit** and no pre-harvest delay



A product with a **high level of performance**, often unmatched for a biocontrol product, that guarantees **yield gains**



A **stable solution** over time (storage at room temperature)



An **easy to use and secure** product for users



A product with an established technical reputation: **Innovation Award** received at the Plant BioProTech Congress in Reims (June 2022).



4

INDUSTRIALIZATION

INDUSTRIALIZATION



Chassieu Industrial R&D Center

2 x 500 L

Production capacity of
bioreactors

500 KG

of active substance
produced per year

PRODUCTION SITE EXPANSION PROJECT




Creation of a new duplicable factory Biocontrol production line

30 T

of additional active substance
Capacity 20x higher than Chassieu

€ 17 M

of investments



A certified site "Label Parc+".

- Preservation and valuation of the environment
- **80%** of roofs covered with photovoltaic panels
- Water recycling in the process
- Biosourced materials

OPTIMIZATION OF INDUSTRIAL PERFORMANCE



2022

APS

APD

PC

2023

Instruction

2024

Construction site

Qualif.

Go Live

NOE (existing test line)



Bioreactors : 2 x 500 L

5 years

Maturity of process developments

500 KG

of active substance produced per year

Pilot line (Chassieu)



Bioreactor : 1 x 3000 L

Implementation of a pilot line:

- To optimize process control
- To develop industrial excellence models
- To launch the plant in the best conditions

INDUSTRIAL PROJECT

USIBIAM (Vaucluse)



Bioreactors : 4 x 5000 L

A.I. 4.0

- Reduce the time, effort and cost required to improve plant performance
- Accelerate real-time and delayed data analysis to identify the root cause of process inefficiencies
- Anticipate energy performance, maintenance and problem resolution

AMOEBBA'S STRATEGY 2024-2026



A volume and profitability strategy

40 tons of AS/year
=
100 000 hectares treated



Vines
(2 771 000 hectares)



Lettuce
(500 000 hectares)



Tomato
(280 000 hectares)



Aromatic herbs
(30 000 hectares)


Price/
ha
50 €



Price/
ha
80 €



Price/
ha
80 €



Price/
ha
200 €





€ 32 M

required for the realization of the project

€ 17 M

Dedicated to the factory construction

€ 15 M

Dedicated to operating expenses over 2023 - 2024

FUNDING

€ 5,9 M

Maximum funding « France 2030 » (35%)

€ 3,2 M

Current bond issue

€ 5 M

Bank loan

€ 18 M

Capital increase

The logo for amoéba features the word "amoéba" in a white, lowercase, sans-serif font. To the right of the text is a stylized circular graphic composed of three overlapping curved segments in shades of blue, green, and light green. A thin white horizontal line passes behind the text and the logo.

amoéba



Social Media
@AmoebaNature



Website
amoeba-nature.com



Contact
contact@amoeba-nature.com

ROADSHOW PRESENTATION 2022